Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials

Affiliations

¹ Université Caen Normandie, ANTICIPE UMR 1086, Department of Pharmacology, Caen, France.
² Department of Pharmacology, Regional Pharmacovigilance Centre, Caen, France.
³ CHU Montpellier, Department of Medical Pharmacology and Toxicology, Desbrest Institute of Epidemiology and Public Health, UMR UA11 University of Montpellier - INSERM, Montpellier, France.
⁴ Université Caen Normandie, ANTICIPE UMR 1086, CHU de Caen, Department of Pharmacology, Pharmaco-Epidemiology Unit, Caen, France.

Lucas Duchemin et al. Diabetes Obes Metab. 2025 Aug.

. 2025 Aug;27(8):4607-4610.

doi: 10.1111/dom.16504. Epub 2025 Jun 5.

¹ Université Caen Normandie, ANTICIPE UMR 1086, Department of Pharmacology, Caen, France.
² Department of Pharmacology, Regional Pharmacovigilance Centre, Caen, France.
³ CHU Montpellier, Department of Medical Pharmacology and Toxicology, Desbrest Institute of Epidemiology and Public Health, UMR UA11 University of Montpellier - INSERM, Montpellier, France.
⁴ Université Caen Normandie, ANTICIPE UMR 1086, CHU de Caen, Department of Pharmacology, Pharmaco-Epidemiology Unit, Caen, France.

No abstract available

Keywords: glucagon‐like peptide‐1 receptor agonists; meta‐analysis; randomized controlled trials; thyroid cancer.

References

1. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes2024. Diabetes Care. 2023;47(Supplement_1):S145‐S157. doi:10.2337/dc24‐S008
1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes2024. Diabetes Care. 2023;47(Supplement_1):S158‐S178. doi:10.2337/dc24‐S009
1. Bezin J, Gouverneur A, Pénichon M, et al. GLP‐1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2022;46(2):384‐390. doi:10.2337/dc22‐1148
1. Hu W, Song R, Cheng R, et al. Use of GLP‐1 receptor agonists and occurrence of thyroid disorders: a meta‐analysis of randomized controlled trials. Front Endocrinol. 2022;13:927859. doi:10.3389/fendo.2022.927859
1. Wang J, Kim CH. Differential risk of cancer associated with glucagon‐like peptide‐1 receptor agonists: analysis of real‐world databases. Endocr Res. 2022;47(1):18‐25. doi:10.1080/07435800.2021.1955255